Canaccord Genuity Group Cuts DRI Healthcare Trust (TSE:DHT.UN) Price Target to C$19.00

DRI Healthcare Trust (TSE:DHT.UN) had its price target lowered by stock analysts at Canaccord Genuity Group from C$19.50 to C$19.00 in a report released on Wednesday, BayStreet.CA reports. The brokerage currently has a “buy” rating on the stock. Canaccord Genuity Group’s price objective indicates a potential upside of 19.65% from the company’s previous close.

A number of other equities research analysts also recently issued reports on DHT.UN. Scotiabank increased their price objective on DRI Healthcare Trust from C$22.00 to C$24.00 and gave the stock an “outperform” rating in a research report on Friday, February 2nd. Raymond James raised DRI Healthcare Trust from an “outperform” rating to a “strong-buy” rating and boosted their price objective for the stock from C$22.00 to C$24.00 in a report on Friday, March 1st. Stifel Nicolaus boosted their price target on shares of DRI Healthcare Trust from C$21.00 to C$22.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. National Bankshares upped their target price on shares of DRI Healthcare Trust from C$22.00 to C$23.50 and gave the stock an “outperform” rating in a research report on Friday, March 1st. Finally, CIBC lifted their price target on DRI Healthcare Trust from C$19.50 to C$20.00 and gave the stock an “outperform” rating in a research note on Wednesday. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of C$21.50.

DRI Healthcare Trust Trading Up 32.8 %

Shares of DRI Healthcare Trust stock opened at C$15.88 on Wednesday. The stock has a 50-day moving average price of C$16.28. DRI Healthcare Trust has a 12-month low of C$8.98 and a 12-month high of C$17.43.

About DRI Healthcare Trust

DRI Healthcare Trust focuses on managing and growing a portfolio of pharmaceutical royalties. It owns a portfolio of 18 royalties derived from the sale of 14 various pharmaceutical products that focuses on eight therapeutic areas. The company was incorporated in 2020 and is headquartered in Toronto, Canada.